(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of -2.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Arcellx's revenue in 2024 is $131,663,000.On average, 6 Wall Street analysts forecast ACLX's revenue for 2024 to be $6,625,919,024, with the lowest ACLX revenue forecast at $3,895,575,770, and the highest ACLX revenue forecast at $11,591,439,229. On average, 6 Wall Street analysts forecast ACLX's revenue for 2025 to be $5,277,440,200, with the lowest ACLX revenue forecast at $2,675,128,600, and the highest ACLX revenue forecast at $7,757,872,940.
In 2026, ACLX is forecast to generate $7,275,012,228 in revenue, with the lowest revenue forecast at $4,772,429,422 and the highest revenue forecast at $10,272,493,824.